Key Points
- COO Julie Rubinstein sold 19,460 shares on March 10 for $285,672.80 and has carried out multiple sales in early March, reducing her stake by 2.94% to 643,471 shares (valued at about $9.45M).
- Adaptive Biotechnologies shares trade around $14.52 with a 1‑year range of $6.26–$20.76 and a $2.24B market cap; the company reported a beat on the quarter (EPS -$0.09 vs. -$0.19) and revenue of $71.7M, up 51% year‑over‑year.
- Analysts are cautiously positive with a consensus rating of “Moderate Buy” and a $18.25 average price target, though coverage is mixed (seven Buys, one Hold, one Sell) and targets range up to $22.00.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 19,460 shares of the business's stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $14.68, for a total value of $285,672.80. Following the completion of the transaction, the chief operating officer owned 643,471 shares in the company, valued at $9,446,154.28. The trade was a 2.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Julie Rubinstein also recently made the following trade(s):
- On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.79, for a total value of $457,617.39.
- On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total value of $484,845.47.
- On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.00, for a total value of $495,056.00.
Adaptive Biotechnologies Price Performance
ADPT stock opened at $14.52 on Wednesday. Adaptive Biotechnologies Corporation has a 1-year low of $6.26 and a 1-year high of $20.76. The business has a 50 day simple moving average of $16.72 and a two-hundred day simple moving average of $15.88. The company has a market capitalization of $2.24 billion, a price-to-earnings ratio of -36.30 and a beta of 2.19.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The firm had revenue of $71.68 million for the quarter, compared to analysts' expectations of $59.38 million. During the same quarter last year, the business posted ($0.23) earnings per share. The company's revenue for the quarter was up 51.0% compared to the same quarter last year. Sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on the company. Morgan Stanley started coverage on Adaptive Biotechnologies in a research report on Monday, December 1st. They set an "equal weight" rating and a $21.00 price objective for the company. Wall Street Zen downgraded Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a research note on Saturday. Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a report on Friday, February 6th. JPMorgan Chase & Co. increased their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Friday, February 6th. Finally, BTIG Research raised their target price on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a "buy" rating in a report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Adaptive Biotechnologies has a consensus rating of "Moderate Buy" and a consensus price target of $18.25.
Get Our Latest Report on Adaptive Biotechnologies
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of ADPT. Brighton Jones LLC raised its stake in shares of Adaptive Biotechnologies by 3.1% in the third quarter. Brighton Jones LLC now owns 23,301 shares of the company's stock valued at $349,000 after acquiring an additional 700 shares during the period. Bouvel Investment Partners LLC grew its holdings in Adaptive Biotechnologies by 2.2% during the 3rd quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company's stock valued at $641,000 after purchasing an additional 904 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Adaptive Biotechnologies by 3.1% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company's stock valued at $355,000 after purchasing an additional 910 shares during the last quarter. California State Teachers Retirement System raised its position in Adaptive Biotechnologies by 1.0% in the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company's stock worth $1,145,000 after purchasing an additional 933 shares during the period. Finally, Captrust Financial Advisors lifted its stake in Adaptive Biotechnologies by 7.6% in the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company's stock worth $184,000 after purchasing an additional 1,119 shares during the last quarter. Institutional investors own 99.17% of the company's stock.
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
